Form 4 for KROS Keros Therapeutics, Inc.
Accepted 2025-02-19 00:00:00 ET · period of report 2025-02-18 · accession 0001415889-25-004597 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-19 | 2025-02-18 | KROS | Regnante Keith | CFO | A - Grant | $0.00 | +44.0K | 44.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-18 | A | A | 44,000 | $0.00 | 44,000 | D | — | — | (F1) Represents a restricted stock unit ("RSU") award. The RSUs vest as follows: 33% of the RSUs shall vest on February 17, 2026, an additional 34% of the total number of RSUs shall vest on August 15, 2026, and the remaining 33% of the total number of RSUs shall vest on February 16, 2027, in each case, subject to the Reporting Person's Continuous Service (as defined in the 2020 Plan) through each applicable vesting date. |